➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Boehringer Ingelheim
Harvard Business School
McKesson
Moodys

Last Updated: August 4, 2020

DrugPatentWatch Database Preview

Litigation Details for Amgen Inc. v. Accord Healthcare, Inc. (D. Del. 2018)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Amgen Inc. v. Accord Healthcare, Inc. (D. Del. 2018)

Docket   Start Trial Date Filed 2018-06-28
Court District Court, D. Delaware Date Terminated 2019-10-21
Cause 35:271 Patent Infringement Assigned To Mitchell S. Goldberg
Jury Demand None Referred To
Parties ACCORD HEALTHCARE, INC.; AMGEN INC.; INTAS PHARMACEUTICALS LIMITED
Patents 6,011,068; 6,211,244; 6,316,460; 6,495,165; 6,733,780; 6,862,890; 7,829,595; 8,288,434; 9,375,405
Attorneys Aaron F. Barkoff; Alejandro Menchaca; Benjamin J. Schladweiler; Derek James Fahnestock; Eric M. Agovino; Jack B. Blumenfeld; Lois Kwasigroch; Maryellen Noreika; Wendy A. Whiteford
Firms Greenberg Traurig, the Nemours Building; Morris, Nichols, Arsht & Tunnell
Link to Docket External link to docket
Small Molecule Drugs cited in Amgen Inc. v. Accord Healthcare, Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .
Biologic Drugs cited in Amgen Inc. v. Accord Healthcare, Inc.

The biologic drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Amgen Inc. v. Accord Healthcare, Inc. (D. Del. 2018)

Date Filed Document No. Description Snippet Link To Document
2019-06-07 66 Claim Construction Chart for the asserted claims of U.S. Patent No. 9,375,405 (“the ’405 patent”). In order to narrow … e.g., ’405 patent, col.6 l.57- the ’405 patent, …: See, patent at Fig. 1, 6:57- e.g., ’405 patent, col.6 8…Evidence2 Intrinsic Evidence2 ’405 patent, “from about 1% to about “from about 1% to about… composition may contain patent at Fig. 1, 6:57- External link to document
2019-06-28 68 Claim Construction Opening Brief s ANDA product”) infringe U.S. Patent No. 9,375,405 (“the ’405 patent”). Since that time, Accord…would literally infringe the claims of the ’405 patent. The Court first rejected Amgen’s argument in its…2018 in the prior litigation involving the ’405 patent. See Amgen Inc. v. Amneal Pharms. LLC et al., …specification or prosecution history of the ’405 patent, and no indication that a person of ordinary skill…2018 21 October 2019 1:18-cv-00956 835 Patent - Abbreviated New Drug Application(ANDA) None External link to document
2019-06-28 69 Claim Construction Opening Brief two disputed claim terms in U.S. Patent No. 9,375,405 (“the ’405 patent,” Rothman Decl. Ex. 1).1 For the… between the patent applicant and the United States Patent and Trademark Office (“Patent Office”)). Phillips…Sensipar® tablets prior to the expiration of the ’405 patent.2 On January 28, 2019, the Court entered a Scheduling…pharmaceutical compositions claimed in the ’405 Patent (“Williams Decl.”). The exhibits referenced herein…STATEMENT OF FACTS The claims of the ’405 patent are directed to pharmaceutical compositions comprising External link to document
2019-06-28 70 Declaration Issue Date: March 8, 2005, US Patent 6,862,890 (of provisional patent application 06/264,988 filed…U.S. Patent No. 9,375,405 (“the ’405 patent,” Rothman Decl. Ex. 1.) 3. The ’405 patent claims…’405 Patent, which I understand may be relevant to the Court’s interpretation of the ’405 Patent claims… In addition, I am an inventor of over 35 patents and patent applications concerning pharmaceutical formulation…spheronization, which are noted in the ’405 patent. (’405 patent, Rothman Decl. Ex. 1, col. 9, ll. 42-45. External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Mallinckrodt
Boehringer Ingelheim
Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.